stockrow
Saturday 7 November 2026
Export AAPG’s income statement to Excel — free account
Ascentage Pharma Group International - Unsponsored ADR
AAPG Healthcare Biotechnology
Ascentage Pharma Group International - Unsponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $82.1 million, down 38.9% from fiscal 2024.
15.30
0.17
+1.12%
Follow AAPG
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 31 | 31 | 134 | 82 | — | +38.1% | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 100.00 | 86.24 | 97.03 | 91.48 | — | (8.5) pt | ||||||
| EBT | — | — | — | — | — | — | 31 | (128) | (54) | (177) | — | n/m | ||||||
| EBT margin, % | — | — | — | — | — | — | 100.00 | (420.24) | (40.31) | (215.30) | — | (315.3) pt | ||||||
| Net income | — | — | — | — | — | — | 0 | (128) | (54) | (177) | (231) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.47 | 0.43 | 1.78 | 0.92 | — | +24.9% | |||||
| Earnings | — | — | — | — | — | — | (1.99) | (1.86) | (0.72) | (2.00) | — | +0.2% | ||||||
| Cash flow | — | — | — | — | — | — | 0.00 | (1.42) | (0.20) | (1.89) | 0.00 | n/m | ||||||
| Capex | — | — | — | — | — | — | 0.00 | (0.11) | (0.04) | (0.04) | 0.00 | n/m | ||||||
| Free cash flow | — | — | — | — | — | — | 0.00 | (1.53) | (0.25) | (1.93) | 0.00 | n/m | ||||||
| Book value | — | — | — | — | — | — | 0.00 | 0.14 | 0.50 | 2.14 | 0.00 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 66 | 71 | 76 | 89 | — | +10.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | — | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.20 | (0.09) | 0.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (100) | (15) | (168) | (318) | +29.6% | |||||
| Capex | — | — | — | — | — | — | — | (8) | (3) | (4) | (11) | (29.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | (108) | (19) | (172) | (329) | +26.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 56 | 42 | 186 | 60 | +81.6% | |||||
| Net debt | — | — | — | — | — | — | — | 97 | 56 | (70) | 29 | n/m | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | 10 | 38 | 191 | 83 | +343.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (74.04) | (15.81) | (38.41) | 0.00 | (38.4) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | (67.80) | (30.31) | (87.57) | 0.00 | (87.6) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 0.00 | (234.96) | (155.65) | 0.00 | (155.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 600 | 567 | 767 | — | +13.1% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.05 | 0.24 | 0.11 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025
Ascentage Pharma Group International - Unsponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADRX ADARx Pharmaceuticals, Inc. | $1.5B | — | — | — | — | — | — | — | Compare |
| IMCR Immunocore Holdings PLC Sponsored ADR | $1.5B | — (loss-making) | — (loss-making) | −1.42% (below 0%: shrinking) | n/m | +440.97% (above 0%: growing) | 99.34% | (13.31%) | Compare |
| QURE uniQure N.V. | $1.5B | — (loss-making) | — (loss-making) | +40.39% (above 0%: growing) | n/m | +27.66% (above 0%: growing) | 95.46% | (1,019.63%) | Compare |
| TYRA Tyra Biosciences, Inc. | $1.4B | — (loss-making) | — | — | n/m | −31.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| AAPG Ascentage Pharma Group International - Unsponsored ADR | $1.4B | — | — | — | — | +17.74% (above 0%: growing) | — | — | |
| OCUL Ocular Therapeutix, Inc. | $1.4B | — (loss-making) | — (loss-making) | +0.12% (above 0%: growing) | n/m | −25.35% (below 0%: shrinking) | 85.08% | (609.34%) | Compare |
| KRSA Korsana Biosciences, Inc. | $1.4B | — (loss-making) | — (loss-making) | −43.24% (below 0%: shrinking) | n/m | −184.69% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ANAB AnaptysBio, Inc. | $1.4B | — (loss-making) | 220× | −7.98% (below 0%: shrinking) | n/m | −141.60% (below 0%: shrinking) | 100.00% | (135.53%) | Compare |
| GPCR Structure Therapeutics Inc. Sponsored ADR | $1.4B | — (loss-making) | — | — | n/m | −119.15% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.4B | — | — | −1.42% | — | −31.34% | 95.46% | (13.31%) |